Hjem › Diffust stort B-celle lymfom › Tennessee
Diffust stort B-celle lymfom kliniske forsøg i Tennessee
19 studier for Diffust stort B-celle lymfom søger deltagere på steder i Tennessee.
Byer i Tennessee
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
- Vanderbilt University/Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07763210A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Tennesse Oncology Chattanooga Downtown, Chattanooga
- Tennessee Oncology, Pllc Nashville, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- The University of Tennessee Medical Center ( Site 0142), Knoxville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06717347A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- SCRI Oncology Partners ( Site 0100), Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07519772A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Tennessee Cancer Specialists ( Site 7000), Knoxville
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05139017A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Tennessee Cancer Specialists ( Site 7004), Knoxville
- SCRI Oncology Partners ( Site 7002), Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07226843A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- SCRI Oncology Partners, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Tennessee Oncology, Chattanooga
- Tennessee Oncology, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06806033Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07284433Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- SCRI Oncology Partners, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Baptist Memorial Hospital and Cancer Center-Memphis, Memphis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. feb. 2026 · NCT05633615Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.